GU Cancers 2024 | Establishing the PROMISE registry of patients with prostate cancer

Channing Paller, MD, The Johns Hopkins University, Baltimore, MD, gives an overview of the PROMISE registry, which aims to document men with prostate cancer with various genetic mutations. Patients will be provided with free genetic screening and counselling, where they will be monitored over two decades. The registry will provide information on the frequency of certain mutations and their responses to therapies, as well as help patient recruitment to trials such as the NePtune trial (NCT05498272). This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.